Latest Tyrosine kinase inhibitors Stories
Combining epigenetic therapy and molecular targeted therapy has shown promising results for combating advanced lung cancer.
Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL).
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer.
RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs.
WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC).
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start.
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.
NEW YORK, Dec.
NEW YORK, Dec. 6, 2010 /PRNewswire/ -- Pfizer Inc.
EAST HANOVER, N.J., Dec.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.